Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 159-166

  Gangawar, Ruchika ^a   Ahirwar, Dinesh ^a   Mandhani, Anil ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCG immunotherapy; Bladder cancer; DNA repair capacity; Polymorphism Recurrence free survival

Indexed keywords

BCG VACCINE;

ADULT; AGED; APEX1 GENE; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; ERCC2 GENE; EXCISION REPAIR; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

ADJUVANTS, IMMUNOLOGIC; AGED; BCG VACCINE; CASE-CONTROL STUDIES; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INDIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 77956920390     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9187-y     Document Type: Article

References (32)

1. Meyer JP, Persad R, Gillatt DA. Use of Bacille Calmette-Guérin in superficial bladder cancer. Postgrad Med J. 2002;78:449-54. doi:10.1136/pmj.78. 922.449. (Pubitemid 34948149)
2. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-22. doi:10.1046/j.1523-5394.2002.106011.x. (Pubitemid 35231626)
3. Merz VW, et al. Analysis of early failures after intravesical instillation therapy with Bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol. 1995;75:180-4. doi:10.1111/ j.1464-410X.1995.tb07307.x.
4. Zhou W, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:359-65.
5. Gu J, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.Clin Cancer Res. 2005;11:1408-15. doi:10.1158/1078-0432.CCR-04-1101. (Pubitemid 40315220)
6. Schaeffer L, et al. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J. 1994;13:2388-92. (Pubitemid 24157613)
7. Coin F, Bergmann E, Tremeau-Bravard A, Egly JM. Mutations in XPB and ERCC2 helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J. 1999;18:1357-66. doi:10.1093/emboj/18.5.1357.
8. Bennett RA, Wilson DM, Wong D, Demple B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc Natl Acad Sci. 1997;94:7166-9. doi:10.1073/pnas.94.14.7166. (Pubitemid 27345286)
9. Lu AL, Li X, Gu Y, Wright PM, Chang DY. Repair of oxidative DNA damage: mechanisms and functions. Cell Biochem Biophys. 2001;35:141-70. doi:10.1385/CBB:35:2:141. (Pubitemid 33622685)
10. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513-30.
11. Sobin LH, Wittekind CH. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 199-202.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1998;16:1215. doi:10.1093/nar/16.3.1215.
13. Rybicki BA, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;1:23-9. doi:10.1158/1055-9965.EPI-03-0053. (Pubitemid 38116616)
14. Sanyal S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34. doi: 10.1093/carcin/bgh058. (Pubitemid 38618524)
15. Ito H, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25:1395-401. doi:10.1093/carcin/bgh 153.
16. Leibovici D, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23:5746-56. doi:10.1200/JCO.2005.01.598.
17. Gangwar R, Manchanda PK, Mittal RD. Implications of XRCC1, XPD and APE1 gene polymorphism in North Indian population: a comparative approach in different ethnic groups worldwide. Genetica. 2008 [Epub ahead of print].
18. Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol.2003;170:964-9. doi:10.1097/01.ju.0000073852.24341.4a. (Pubitemid 36999613)
19. Mitra S, Boldogh I, Izumi T, Hazra TK. Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage. Environ Mol Mutagen. 2001;38:180-90. doi:10.1002/em.1070. (Pubitemid 33069949)
20. Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelöv E, Hemminki K, et al. Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol. 2007;46:31-41. doi:10.1080/ 02841860600812693.
21. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. Highorder interactions among genetic variants in DNA BER pathway and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2007;16:84-91. doi:10.1158/1055-9965.EPI-06-0712. (Pubitemid 46174268)
22. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, et al. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:878-84. doi:10.1158/1055-9965.EPI-04-0235. (Pubitemid 40478551)
23. Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1004-11.
24. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030-7. doi:10.1093/carcin/bgi284.
25. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;9: 561-70. doi:10.1038/sj.bjc.6603290. (Pubitemid 44325895)
26. Wang F, Chang D, Hu F, Sui H, Han B, Li D, et al. DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev. 2008;17:507-17.
27. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001;61: 1354-7.
28. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002;23:599-603. doi:10.1093/carcin/23.4.599.
29. Capella G, Pera G, Sala N, Agudo A, Rico F, Giudicce GD, et al. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol. 2008;37:1316-25. doi:10.1093/ije/dyn145.
30. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated nonsmall-cell lung cancer patients. Ann Oncol. 2006;17:668-75. doi:10.1093/annonc/mdj135.
31. Hansen RD, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007;619:68-80. doi:10.1016/j.mrfmmm. 2007.02.002.
32. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol. 2007;107(Suppl 1):S223-9. doi:10.1016/j.ygyno.2007.07.024. (Pubitemid 47487477)